Mirum Pharmaceuticals (NASDAQ: MIRM) has emerged as a standout in the biotech sector, with its stock surging over 120% in the past year. The company markets three approved therapies for rare genetic liver diseases and reported a remarkable 50% year-over-year increase in net product sales for Q4 2025, driven largely by a 69% sales jump for its leading drug, Livmarli. Despite projected negative free cash flow this year due to increased R&D spending, Mirum anticipates a return to positive cash flow by 2027.

The significance of Mirum’s performance lies in its robust pipeline, with peak sales estimates for upcoming candidates exceeding $4 billion. The company is set to announce pivotal clinical trial results over the next 18 months, which could further bolster its market position. With a current market cap of approximately $5.8 billion, analysts suggest that Mirum could be valued at around $26 billion if its therapies meet expectations.

For investors, Mirum presents a compelling opportunity, but caution is advised due to inherent biotech risks. Diversifying portfolios remains essential, even as Mirum’s upcoming data releases could catalyze significant market movements.

Source: fool.com